Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
909 articles with Moderna, Inc.
-
A small research study published in Jama shows people with a lower body mass index (BMI) tended to maintain immunity against COVID-19 longer.
-
Based on topline data, Pfizer stated that three doses of the COVID-19 vaccine met all immunobridging criteria required for EUA. The FDA's advisory committee will meet June 15 to discuss the matter.
-
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
-
Moderna to Present at the UBS 2022 Global Healthcare Conference
5/18/2022
Moderna, Inc. announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET.
-
Scientists in New Zealand have found that mRNA-based COVID-19 vaccines produce greater antibody levels compared to adenovirus vector-based ones across major COVID-19 variants.
-
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
5/18/2022
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity.
-
Moderna held its first in-person Science and Technology Day since 2019. Notably, the company shared information about its new inhalable lipid nanoparticles (LNPs).
-
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
5/17/2022
Moderna, Inc. today announced new research findings as part of the Company's fifth annual Science and Technology Day. Moderna continues to highlight investments in the expansion of the utility of the mRNA platform, characterization of the Company's vaccines, biodistribution of vaccines, and using clinical data to predict vaccine dosing.
-
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
-
Less than one month after he was appointed as chief financial officer of Moderna, Jorge Gomez abruptly departed the company due to an ongoing investigation at his former company.
-
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
-
Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
5/11/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the Company, effective immediately.
-
The 12 Top Biotech Companies Hiring Now
5/10/2022
According to recent BioSpace research, job seekers are on the prowl for roles that are interesting and pay well with good benefits at reputable companies. -
Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in its COVID-19 vaccine.
-
Moderna to Host Annual Science and Technology Day on May 17, 2022
5/9/2022
Moderna, Inc. today announced that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.
-
Life Science industries are seeing massive financial fluctuations in how they're handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
-
Moderna held its 2022 Q1 earnings call this morning announcing $6.1 billion in revenue and robust plans to roll out COVID-19 boosters this fall.
-
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
5/4/2022
Moderna, Inc. today reported financial results and provided business updates for the first quarter of fiscal year 2022.
-
New studies suggest that the virus may aggravate childhood asthma after infection. For that and more COVID-19 news, continue reading.
-
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”